Privia Health Group, Inc.(PRVA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #888 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PRVA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Privia Health Group, Inc. (PRVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRVA at 60.1/100 on a 32-signal composite quality model, placing it at rank #888 of 2,961 stocks — the top half of the AI-ranked universe. PRVA scores in the top quartile across earnings quality (94.4), revenue growth (78.5). Areas of concern include profitability (39.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Privia Health Group, Inc. reports quarterly revenue of $632.6M, net income of $9.0M, an operating margin of 1.9%. Top institutional holders of PRVA by reported 13-F value include BlackRock, FMR, Durable Capital Partners, based on the most recent SEC filings. PRVA trades on the Nasdaq exchange and files with the SEC under CIK 1759655. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Privia Health Group, Inc. directly from SEC EDGAR. Privia Health Group, Inc.'s 13F Pro composite quality score has ranged between 55 and 61 since 2026, currently 60.1 — an improving long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
Q2 2026
$632.6M
Net Income
Q2 2026
$9.0M
Operating Margin
Q2 2026
1.9%
ROIC
Q2 2026
6.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+22.3% YoYNet Income
+59.3% YoYOperating Income
+101.6% YoYEPS (Diluted)
+63.6% YoYTotal Assets
+20.6% YoYOp. Cash Flow
+49.5% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.12B +22.3% | $1.74B +4.7% | $1.66B +22.2% | $1.36B +40.4% | $966.2M +18.3% | $817.1M |
| Net Income | $22.9M +59.3% | $14.4M -37.7% | $23.1M +368.8% | $-8.6M +95.4% | $-188.2M -702.5% | $31.2M |
| Operating Income | $34.2M +101.6% | $17.0M -17.8% | $20.6M +208.0% | $-19.1M +91.2% | $-217.4M -956.7% | $25.4M |
| EPS (Diluted) | $0.18 +63.6% | $0.11 -42.1% | $0.19 +337.5% | $-0.08 +95.6% | $-1.83 -654.5% | $0.33 |
| Total Assets | $1.37B +20.6% | $1.14B +13.6% | $999.9M +26.1% | $792.8M +15.5% | $686.4M +108.6% | $329.0M |
| Operating Cash Flow | $163.4M +49.5% | $109.3M +35.3% | $80.8M +71.2% | $47.2M -14.3% | $55.1M +41.6% | $38.9M |
| Free Cash Flow | — | — | $80.7M +71.3% | $47.1M -13.6% | $54.5M +41.5% | $38.5M |
Get alerted when PRVA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Privia Health Group, Inc. including:
Top Institutional Holders of PRVA
BlackRock, Inc.
$550.7M21,402,417 shFMR LLC
$330.6M12,848,437 shDurable Capital Partners LP
$299.4M11,635,948 shVANGUARD PORTFOLIO MANAGEMENT LLC
$169.1M6,572,384 shRubicon Founders LLC
$153.6M5,971,079 shVANGUARD CAPITAL MANAGEMENT LLC
$132.7M5,156,720 shSTATE STREET CORP
$126.2M4,905,789 shVan Berkom & Associates Inc.
$95.5M3,711,623 shGEODE CAPITAL MANAGEMENT, LLC
$80.6M3,130,473 shRIVERBRIDGE PARTNERS LLC
$77.2M2,998,597 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $550.7M | 21,402,417 |
| FMR LLC | $330.6M | 12,848,437 |
| Durable Capital Partners LP | $299.4M | 11,635,948 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $169.1M | 6,572,384 |
| Rubicon Founders LLC | $153.6M | 5,971,079 |
| VANGUARD CAPITAL MANAGEMENT LLC | $132.7M | 5,156,720 |
| STATE STREET CORP | $126.2M | 4,905,789 |
| Van Berkom & Associates Inc. | $95.5M | 3,711,623 |
| GEODE CAPITAL MANAGEMENT, LLC | $80.6M | 3,130,473 |
| RIVERBRIDGE PARTNERS LLC | $77.2M | 2,998,597 |
Companies Similar to PRVA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Pennant Group, Inc.
LifeStance Health Group, Inc.
Alignment Healthcare, Inc.
MERIT MEDICAL SYSTEMS INC
Addus HomeCare Corp
BRIGHT HORIZONS FAMILY SOLUTIONS INC.
RadNet, Inc.
REPLIGEN CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PRVA on your watchlist
Track score changes the day Privia Health Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRVA a good stock to buy?
13F Pro's AI-powered analysis of Privia Health Group, Inc. (PRVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRVA are available on the PRVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRVA is classified as a mid company.
Which hedge funds own PRVA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Privia Health Group, Inc.'s investment landscape.